Publication:
p38γ is essential for cell cycle progression and liver tumorigenesis.

dc.contributor.authorTomas-Loba, Antonia
dc.contributor.authorManieri, Elisa
dc.contributor.authorGonzalez-Teran, Barbara
dc.contributor.authorMora, Alfonso
dc.contributor.authorLeiva-Vega, Luis
dc.contributor.authorSantamans, Ayelen M
dc.contributor.authorRomero-Becerra, Rafael
dc.contributor.authorRodríguez, Elena
dc.contributor.authorPintor-Chocano, Aránzazu
dc.contributor.authorFeixas, Ferran
dc.contributor.authorLopez, Juan Antonio
dc.contributor.authorCaballero, Beatriz
dc.contributor.authorTrakala, Marianna
dc.contributor.authorBlanco, Óscar
dc.contributor.authorTorres, Jorge L
dc.contributor.authorHernández-Cosido, Lourdes
dc.contributor.authorMontalvo-Romeral, Valle
dc.contributor.authorMatesanz, Nuria
dc.contributor.authorRoche-Molina, Marta
dc.contributor.authorBernal, Juan Antonio
dc.contributor.authorMischo, Hannah
dc.contributor.authorLeón, Marta
dc.contributor.authorCaballero, Ainoa
dc.contributor.authorMiranda-Saavedra, Diego
dc.contributor.authorRuiz-Cabello, Jesus
dc.contributor.authorNevzorova, Yulia A
dc.contributor.authorCubero, Francisco Javier
dc.contributor.authorBravo, Jerónimo
dc.contributor.authorVazquez, Jesus
dc.contributor.authorMalumbres, Marcos
dc.contributor.authorMarcos, Miguel
dc.contributor.authorOsuna, Sílvia
dc.contributor.authorSabio, Guadalupe
dc.contributor.funderFundación La Caixa
dc.contributor.funderFundación Ramón Areces
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderUnión Europea
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)
dc.contributor.funderEuropean Foundation for the Study of Diabetes
dc.contributor.funderFundación BBVA
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderComunidad de Madrid (España)
dc.contributor.funderDeutsche Forschungsgemeinschaft (Alemania)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderJunta de Castilla y León (España)
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderFundación La Marató TV3
dc.date.accessioned2020-12-29T08:34:26Z
dc.date.available2020-12-29T08:34:26Z
dc.date.issued2019-04
dc.description.abstractThe cell cycle is a tightly regulated process that is controlled by the conserved cyclin-dependent kinase (CDK)-cyclin protein complex1. However, control of the G0-to-G1 transition is not completely understood. Here we demonstrate that p38 MAPK gamma (p38γ) acts as a CDK-like kinase and thus cooperates with CDKs, regulating entry into the cell cycle. p38γ shares high sequence homology, inhibition sensitivity and substrate specificity with CDK family members. In mouse hepatocytes, p38γ induces proliferation after partial hepatectomy by promoting the phosphorylation of retinoblastoma tumour suppressor protein at known CDK target residues. Lack of p38γ or treatment with the p38γ inhibitor pirfenidone protects against the chemically induced formation of liver tumours. Furthermore, biopsies of human hepatocellular carcinoma show high expression of p38γ, suggesting that p38γ could be a therapeutic target in the treatment of this disease.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipG.S. (RYC-2009-04972), F.J.C. (RYC-2014-15242), and Y.A.N. (RYC-2015-17438) are investigators of the Ramón y Cajal Program. E.M. and M.T. were awarded La Caixa fellowships and R.R.-B. was a fellow of the Fundación Ramón Areces-UAM and FPU. B.G.-T. is a fellow of the FPI Severo Ochoa CNIC program (SVP-2013-067639). F.J.C. is a Gilead Liver Research Scholar. This work was funded by grants supported in part by funds from the European Regional Development Fund: the European Union’s Seventh Framework Programme (FP7/2007-2013) ERC 260464, EFSD/Lilly European Diabetes Research Programme Dr Sabio, 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (InvestigadoresBBVA-2017) IN[17]_BBM_BAS_0066, MINECO-FEDER SAF2016-79126-R, and Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/ BMD-3733 to G.S.; Juan de la Cierva and MINECO SAF2014-61233-JIN to A.T.-L.; the European Community for MSCA-IF-2014-EF-661160-MetAccembly grant to F.F.; Spanish MINECO CTQ2014-59212-P, European Community for CIG project (PCIG14-GA-2013-630978), and European Research Council (ERC) under the European Union’s Horizon 2020 (ERC-2015-StG-679001- NetMoDEzyme) to S.O.; the German Research Foundation (SFB/TRR57/P04 and DFG NE 2128/2-1) and MINECO SAF2017-87919R to Y.A.N.; EXOHEP-CM S2017/BMD-3727 and the COST Action CA17112, MINECO SAF2016-78711, and the AMMF Cholangiocarcinoma Charity 2018/117 to F.J.C.; MINECO (SAF2015-69920-R co-funded by ERDF-EU), the Consolider-Ingenio 2010 Programme (SAF2014-57791-REDC), Excellence Network CellSYS (BFU2014- 52125-REDT), and the iLUNG Programme (B2017/BMD-3884) from the Comunidad de Madrid to M. Malumbres; MINECO SAF2015-67077-R and SAF2017-89901-R to J.B.; MINECO (BIO2015-67580-P), Carlos III Institute of Health-Fondo de Investigación Sanitaria (ProteoRed PRB3, IPT17/0019 - ISCIII-SGEFI/ERDF), Fundación La Marató and ‘La Caixa’ Banking Foundation (HR17-00247) to J.V.; ISCIII and FEDER PI16/01548 and Junta de Castilla y León GRS 1362/A/16 and INT/M/17/17 to M. Marcos; Junta de Castilla y León GRS 1356/A/16 and GRS 1587/A/17 to J.L.-T.; and MCNU (SAF2017- 84494-C2-1-R) to J.R.-C. The CNIC is supported by the Ministerio de Ciencia, Innovación y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).es_ES
dc.format.number7753es_ES
dc.format.page557-560es_ES
dc.format.volume568es_ES
dc.identifier.citationNature. 2019; 568(7735):557-60es_ES
dc.identifier.doi10.1038/s41586-019-1112-8es_ES
dc.identifier.journalNaturees_ES
dc.identifier.pubmedID30971822es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11565
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RYC-2009-04972es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RYC-2014-15242es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RYC-2015-17438es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/260464es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2016-79126-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2014-61233-JINes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CTQ2014-59212-Pes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/679001es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-87919Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2016-78711es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-69920-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2014-57791-REDCes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-67077-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-89901-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BIO2015-67580-Pes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017- 84494-C2-1-Res_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41586-019-1112-8es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Papel de las quinasas activadas por el estrés en el desarrollo de enfermedades cardiovasculares, diabetes y cánceres_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Cardiomiopatías de origen genéticoes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómicaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshCell Cyclees_ES
dc.subject.meshAgedes_ES
dc.subject.meshAnimalses_ES
dc.subject.meshCarcinogenesises_ES
dc.subject.meshCarcinoma, Hepatocellulares_ES
dc.subject.meshCell Line, Tumores_ES
dc.subject.meshCyclin-Dependent Kinaseses_ES
dc.subject.meshFemalees_ES
dc.subject.meshHepatocyteses_ES
dc.subject.meshHumanses_ES
dc.subject.meshLiveres_ES
dc.subject.meshLiver Neoplasmses_ES
dc.subject.meshMalees_ES
dc.subject.meshMicees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshMitogen-Activated Protein Kinase 12es_ES
dc.subject.meshPhosphorylationes_ES
dc.subject.meshPyridoneses_ES
dc.subject.meshRetinoblastoma Proteines_ES
dc.subject.meshSequence Homologyes_ES
dc.subject.meshSubstrate Specificityes_ES
dc.titlep38γ is essential for cell cycle progression and liver tumorigenesis.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication14faf566-fda5-459f-8e60-695838156fc6
relation.isAuthorOfPublication88c450ec-5a81-490a-b236-73e59d9df262
relation.isAuthorOfPublication0dc71b91-44e2-461b-8cef-e13b10191736
relation.isAuthorOfPublicationbc42fc37-5614-4176-852f-4210784143e8
relation.isAuthorOfPublication765eed5e-47c5-408b-b169-4aebaf54059a
relation.isAuthorOfPublication79e0f347-1982-44a8-8b6f-f8a304ff83d8
relation.isAuthorOfPublicationd79f2bf1-6f13-4b5f-9ae3-4c0ea06e9dcb
relation.isAuthorOfPublicationf72c7d1a-c03b-4445-ac1f-9fe29ec072dc
relation.isAuthorOfPublicationaaf8ce45-f799-4a44-8a6b-ccb1c5f11242
relation.isAuthorOfPublication2067ffda-2a8d-4797-a226-9ef40389b1dd
relation.isAuthorOfPublication89973830-2cd8-4908-8cd6-47df9dd86b4d
relation.isAuthorOfPublication2ce72629-a066-40f8-ad95-1a476ff6aa77
relation.isAuthorOfPublicationb3f37c3e-89ec-49f6-bfe5-a720d70d10ee
relation.isAuthorOfPublication845644de-01dd-4517-ab89-a07183d31248
relation.isAuthorOfPublication9743763b-919c-4fa9-a53c-57c41be5e0ac
relation.isAuthorOfPublication7de1300f-8563-434d-b693-41b7c8c6fdd1
relation.isAuthorOfPublication.latestForDiscovery14faf566-fda5-459f-8e60-695838156fc6

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
p38gammaEssentialCellCycle_2019.pdf
Size:
3.48 MB
Format:
Adobe Portable Document Format
Description:
Artículo